SCHEMBL3278733

SCHEMBL3278733

c1ccc(-c2[nH]c(-c3ccccc3)c(-c3ccccc3)c2-c2ccccc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 3/20 0.62
ESR2 Q92731 3/20 0.62
KDM4E B2RXH2 2/20 0.52
ALDH1A1 P00352 2/20 0.52
PLA2G10 O15496 1/20 0.52
GAA P10253 1/20 0.52
HPGD P15428 1/20 0.52
HSD17B10 Q99714 1/20 0.52
MDM2 Q00987 2/20 0.48
MAPK1 P28482 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
MAPT P10636 2/20 0.46
PIM1 P11309 1/20 0.46
GFER P55789 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
LMNA P02545 1/20 0.46
HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9775858 0.86 HSD17B10 (0.58) ESR1ESR2KDM4EALDH1A1PLA2G10
SCHEMBL21310428 0.86 HSD17B10 (0.58) ESR1ESR2KDM4EALDH1A1PLA2G10
SCHEMBL28825756 0.83 ESR1 (0.52) ESR1ESR2KDM4EALDH1A1PLA2G10
SCHEMBL28338869 0.83 ESR1 (0.52) ESR1ESR2KDM4EALDH1A1PLA2G10
SCHEMBL28595339 0.83 ESR1 (0.52) ESR1ESR2KDM4EALDH1A1PLA2G10
SCHEMBL7624177 0.83 ESR1 (0.52) ESR1ESR2KDM4EALDH1A1PLA2G10
SCHEMBL26567857 0.78 TDP1 (0.48) ESR1ESR2HSD17B10MDM2MAPK1
SCHEMBL3864662 0.78 ESR1 (1.00) ESR1ESR2KDM4EALDH1A1HPGD
SCHEMBL22403888 0.78 ESR1 (0.63) ESR1ESR2KDM4EALDH1A1PLA2G10
SCHEMBL6422263 0.78 KDM4E (0.54) ESR1ESR2KDM4EALDH1A1PLA2G10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3458522-B1 PROCESS FOR THE PREPARATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS HAVING A HIGH DEGREE OF PURITY ICROM SPA (IT) 2024-01-03 EP claimed
CN-115449108-B proton exchange membrane 中国科学院福建物质结构研究所 2023-11-17 CN claimed
CN-115449108-A Proton exchange membrane 中国科学院福建物质结构研究所 2022-12-09 CN claimed
CN-113277970-B Tetraphenylpyrrole derivative containing carbonyl and preparation method and application thereof 南京工业大学 2022-10-18 CN claimed
CN-113277970-A Tetraphenylpyrrole derivative containing carbonyl and preparation method and application thereof 南京工业大学 2021-08-20 CN claimed
US-10723710-B2 Process for the preparation of diaminophenothiazinium compounds having a high degree of purity ICROM S.P.A. (IT) 2020-07-28 US claimed
US-20190185440-A1 PROCESS FOR THE PREPARATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS HAVING A HIGH DEGREE OF PURITY ICROM S.P.A. (IT) 2019-06-20 US claimed
EP-3458522-A1 PROCESS FOR THE PREPARATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS HAVING A HIGH DEGREE OF PURITY Icrom SpA (IT) 2019-03-27 EP claimed
US-9856364-B2 Stabilized reversible polymer composition XEROX CORPORATION (US) 2018-01-02 US claimed
WO-2017199162-A1 PROCESS FOR THE PREPARATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS HAVING A HIGH DEGREE OF PURITY ICROM S.P.A. (IT) 2017-11-23 WO claimed
US-20140353549-A1 STABILIZED REVERSIBLE POLYMER COMPOSITION XEROX CORPORATION (US) 2014-12-04 US claimed
CN-102186643-A Enhanced surfaces, coatings and related methods INNOVA METERIALS LLC 2011-09-14 CN claimed
US-20050080260-A1 Preparation of prodrugs for selective drug delivery LUMINIDE 2005-04-14 US claimed
CN-1089086-C Luminandide medicine MILLS RANDELL L (US) 2002-08-14 CN claimed
EP-0414730-B1 Chemical Compounds and pharmaceutical compositions capable of releasing a drug MILLS RANDELL L (US) 1999-12-15 EP claimed
US-5773592-A COMPRISES A CHEMILUMINESCENT MOIETY, A PHOTOCHROMIC MOIETY AND A BIOLOGICALLY ACTIVE AGENT CAPABLE OF BEING RELEASED MILLS RANDELL LEE (US) 1998-06-30 US claimed
EP-0717054-A2 Stable free radical polymerization process and thermoplastic materials produced therefrom XEROX CORPORATION (US) 1996-06-19 EP claimed
US-5449724-A Stable free radical polymerization process and thermoplastic materials produced therefrom XEROX CORPORATION (US) 1995-09-12 US claimed
JP-58176639-A None JP disclosed
US-4082551-A GOOD ADHESION AND BLOCKING POSITIVE CHARGED PARTICLES EASTMAN KODAK COMPANY (US) 1978-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080260-A1 Preparation of prodrugs for selective drug delivery APEH, PAH, ALAD ESR1 362/4885ESR2 507/4885KDM4E 3072/4885
US-10723710-B2 Process for the preparation of diaminophenothiazinium compounds having a high degree of purity DDT, QDPR, DDC ESR1 4575/4885ESR2 4454/4885KDM4E 1531/4885
US-20190185440-A1 PROCESS FOR THE PREPARATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS HAVING A HIGH DEGREE OF PURITY DDT, QDPR, DDC ESR1 4575/4885ESR2 4454/4885KDM4E 1531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.